InSolutionTM ALLN

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Reversible: no

Product does not compete with ATP.

Target K_i: 190 nM, 220 nM, 150 nM, 500 pM, against calpain I, calpain II, cathepsin B, and cathepsin L, respectively

Primary Targetcalpain 1

Cell permeable: yes

General description

A 10 mM solution of ALLN (Cat. No. 208719) in anhydrous DMSO. Inhibitor of calpain I (K_i = 190 nM), calpain II (K_i = 220 nM), cathepsin B (K_i = 150 nM), and cathepsin L (K_i = 0.5 nM). Inhibits neutral cysteine proteases and proteasome (K_i = 6 µM). Protects against neuronal damage caused by hypoxia and ischemia. Inhibits apoptosis in thymocytes and metamyelocytes. Inhibits cell cycle progression at the G₁/S border and metaphase/anaphase in CHO cells by inhibiting cyclin B degradation. Also prevents nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. Inhibits the proteolysis of IkB-α and IkB-β by the ubiquitin-proteasome complex.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Milligan, S.A., et al. 1996. Arch. Biochem. Biophys.335, 388.Griscavage, J.M., et al. 1995. Biochem. Biophys. Res. Commun.215, 721.Squier, M.K., et al. 1994. J. Cell Physiol.159, 229.Rami, J., and Kreiglstein, J. 1993. Brain Res.609, 67.

Packaging

5 mg in Glass bottle

Packaged under inert gas

Physical form

A 10 mM (5 mg/1.30 ml) solution of ALLN (Cat. No. 208719) in DMSO.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C).

Warning

Toxicity: Flammable (J)